Switzerland: Alcon uses debt for Aerie acquisition

Alcon, the largest eye care device company in the world, is acquiring Nasdaq-listed Aerie Pharmaceuticals, a US-based company focused on the discovery, development, manufacturing and commercialization of ophthalmic therapies. The purchase price of US$15.25 per share represents a premium of 37% to Aerie’s last closing price and represents an equity value of approximately US$770m. Alcon…